APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Orally Administered Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Orally Administered Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174020350321 December 2025194 pages

Choose your research edition.

Industry ResearchOrally Administered Vaccine Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Orally Administered Vaccine Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Orally Administered Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orally Administered Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Orally Administered Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Orally Administered Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Orally Administered Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Orally Administered Vaccine include Lanzhou Institute, Sanofi, Merck, GSK, Tiantan Biological, Valneva, Vabiotech, Shanghai United Cell and Serum Institute, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Orally Administered Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orally Administered Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orally Administered Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Orally Administered Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Orally Administered Vaccine Segment by Company

Lanzhou Institute

Sanofi

Merck

GSK

Tiantan Biological

Valneva

Vabiotech

Shanghai United Cell

Serum Institute

PaxVax

Panacea Biotec Ltd

Halfkin Bio-Pharmaceuticals

EuBiologics

Bio-Med

Bibcol

Orally Administered Vaccine Segment by Type

Rotavirus Vaccine

Oral Polio Vaccine

Cholera Vaccine

Other

Orally Administered Vaccine Segment by Application

Public

Private

Orally Administered Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orally Administered Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orally Administered Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orally Administered Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Orally Administered Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Orally Administered Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Orally Administered Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Orally Administered Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Orally Administered Vaccine Industry Trends Table 2. Orally Administered Vaccine Industry Drivers Table 3. Orally Administered Vaccine Industry Opportunities and Challenges Table 4. Orally Administered Vaccine Industry Restraints Table 5. Global Orally Administered Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Orally Administered Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Orally Administered Vaccine Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Orally Administered Vaccine Sales Market Share by Manufacturers Table 9. Global Orally Administered Vaccine Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Orally Administered Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Orally Administered Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Orally Administered Vaccine Manufacturers, Product Type & Application Table 13. Global Orally Administered Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Orally Administered Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Rotavirus Vaccine Table 17. Major Manufacturers of Oral Polio Vaccine Table 18. Major Manufacturers of Cholera Vaccine Table 19. Major Manufacturers of Other Table 20. Global Orally Administered Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Orally Administered Vaccine Sales by Type (2021-2026) & (k units) Table 22. Global Orally Administered Vaccine Sales by Type (2027-2032) & (k units) Table 23. Global Orally Administered Vaccine Sales Market Share by Type (2021-2026) Table 24. Global Orally Administered Vaccine Sales Market Share by Type (2027-2032) Table 25. Global Orally Administered Vaccine Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 26. Global Orally Administered Vaccine Revenue by Type (2021-2026) & (k units) Table 27. Global Orally Administered Vaccine Revenue by Type (2027-2032) & (k units) Table 28. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2026) Table 29. Global Orally Administered Vaccine Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Public Table 31. Major Manufacturers of Private Table 32. Global Orally Administered Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global Orally Administered Vaccine Sales by Application (2021-2026) & (k units) Table 34. Global Orally Administered Vaccine Sales by Application (2027-2032) & (k units) Table 35. Global Orally Administered Vaccine Sales Market Share by Application (2021-2026) Table 36. Global Orally Administered Vaccine Sales Market Share by Application (2027-2032) Table 37. Global Orally Administered Vaccine Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Orally Administered Vaccine Revenue by Application (2021-2026) & (k units) Table 39. Global Orally Administered Vaccine Revenue by Application (2027-2032) & (k units) Table 40. Global Orally Administered Vaccine Revenue Market Share by Application (2021-2026) Table 41. Global Orally Administered Vaccine Revenue Market Share by Application (2027-2032) Table 42. Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global Orally Administered Vaccine Sales by Region (2021-2026) & (k units) Table 44. Global Orally Administered Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Orally Administered Vaccine Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global Orally Administered Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 49. North America Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 50. Europe Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 52. Europe Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa Orally Administered Vaccine Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa Orally Administered Vaccine Sales by Country (2027-2032) & (k units) Table 59. Global Orally Administered Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Orally Administered Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Orally Administered Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Orally Administered Vaccine Revenue Market Share by Region (2021-2026) Table 63. Global Orally Administered Vaccine Revenue Market Share by Region (2027-2032) Table 64. Lanzhou Institute Company Information Table 65. Lanzhou Institute Business Overview Table 66. Lanzhou Institute Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Lanzhou Institute Orally Administered Vaccine Product Portfolio Table 68. Lanzhou Institute Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Orally Administered Vaccine Product Portfolio Table 73. Sanofi Recent Development Table 74. Merck Company Information Table 75. Merck Business Overview Table 76. Merck Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Merck Orally Administered Vaccine Product Portfolio Table 78. Merck Recent Development Table 79. GSK Company Information Table 80. GSK Business Overview Table 81. GSK Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GSK Orally Administered Vaccine Product Portfolio Table 83. GSK Recent Development Table 84. Tiantan Biological Company Information Table 85. Tiantan Biological Business Overview Table 86. Tiantan Biological Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Tiantan Biological Orally Administered Vaccine Product Portfolio Table 88. Tiantan Biological Recent Development Table 89. Valneva Company Information Table 90. Valneva Business Overview Table 91. Valneva Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Valneva Orally Administered Vaccine Product Portfolio Table 93. Valneva Recent Development Table 94. Vabiotech Company Information Table 95. Vabiotech Business Overview Table 96. Vabiotech Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Vabiotech Orally Administered Vaccine Product Portfolio Table 98. Vabiotech Recent Development Table 99. Shanghai United Cell Company Information Table 100. Shanghai United Cell Business Overview Table 101. Shanghai United Cell Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Shanghai United Cell Orally Administered Vaccine Product Portfolio Table 103. Shanghai United Cell Recent Development Table 104. Serum Institute Company Information Table 105. Serum Institute Business Overview Table 106. Serum Institute Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Serum Institute Orally Administered Vaccine Product Portfolio Table 108. Serum Institute Recent Development Table 109. PaxVax Company Information Table 110. PaxVax Business Overview Table 111. PaxVax Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. PaxVax Orally Administered Vaccine Product Portfolio Table 113. PaxVax Recent Development Table 114. Panacea Biotec Ltd Company Information Table 115. Panacea Biotec Ltd Business Overview Table 116. Panacea Biotec Ltd Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio Table 118. Panacea Biotec Ltd Recent Development Table 119. Halfkin Bio-Pharmaceuticals Company Information Table 120. Halfkin Bio-Pharmaceuticals Business Overview Table 121. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio Table 123. Halfkin Bio-Pharmaceuticals Recent Development Table 124. EuBiologics Company Information Table 125. EuBiologics Business Overview Table 126. EuBiologics Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. EuBiologics Orally Administered Vaccine Product Portfolio Table 128. EuBiologics Recent Development Table 129. Bio-Med Company Information Table 130. Bio-Med Business Overview Table 131. Bio-Med Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Bio-Med Orally Administered Vaccine Product Portfolio Table 133. Bio-Med Recent Development Table 134. Bibcol Company Information Table 135. Bibcol Business Overview Table 136. Bibcol Orally Administered Vaccine Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Bibcol Orally Administered Vaccine Product Portfolio Table 138. Bibcol Recent Development Table 139. Key Raw Materials Table 140. Raw Materials Key Suppliers Table 141. Orally Administered Vaccine Distributors List Table 142. Orally Administered Vaccine Customers List Table 143. Research Programs/Design for This Report Table 144. Authors List of This Report Table 145. Secondary Sources Table 146. Primary Sources List of Figures Figure 1. Orally Administered Vaccine Product Image Figure 2. Global Orally Administered Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orally Administered Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Orally Administered Vaccine Sales (2021-2032) & (k units) Figure 5. Global Orally Administered Vaccine Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Orally Administered Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Rotavirus Vaccine Image Figure 9. Oral Polio Vaccine Image Figure 10. Cholera Vaccine Image Figure 11. Other Image Figure 12. Global Orally Administered Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Orally Administered Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Orally Administered Vaccine Sales Market Share by Type (2021-2032) Figure 15. Global Orally Administered Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Orally Administered Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2032) Figure 18. Public Image Figure 19. Private Image Figure 20. Global Orally Administered Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global Orally Administered Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Orally Administered Vaccine Sales Market Share by Application (2021-2032) Figure 23. Global Orally Administered Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global Orally Administered Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Orally Administered Vaccine Revenue Market Share by Application (2021-2032) Figure 26. North America Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America Orally Administered Vaccine Sales Market Share by Country (2021-2032) Figure 28. U.S. Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe Orally Administered Vaccine Sales Market Share by Country (2021-2032) Figure 33. Germany Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 34. France Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific Orally Administered Vaccine Sales Market Share by Country (2021-2032) Figure 40. China Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 44. India Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa Orally Administered Vaccine Sales Market Share by Country (2021-2032) Figure 48. Brazil Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile Orally Administered Vaccine Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global Orally Administered Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Orally Administered Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Figure 59. North America Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Figure 61. Europe Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Orally Administered Vaccine Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Orally Administered Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Orally Administered Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Rotavirus Vaccine
  • Oral Polio Vaccine
  • Cholera Vaccine
  • Other
Applications
  • Public
  • Private
Companies covered
  • Lanzhou Institute
  • Sanofi
  • Merck
  • GSK
  • Tiantan Biological
  • Valneva
  • Vabiotech
  • Shanghai United Cell
  • Serum Institute
  • PaxVax
  • Panacea Biotec Ltd
  • Halfkin Bio-Pharmaceuticals
  • EuBiologics
  • Bio-Med
  • Bibcol

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Orally Administered Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Orally Administered Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Orally Administered Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Orally Administered Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Orally Administered Vaccine Market Dynamics
  1. 2.1 Orally Administered Vaccine Industry Trends
  2. 2.2 Orally Administered Vaccine Industry Drivers
  3. 2.3 Orally Administered Vaccine Industry Opportunities and Challenges
  4. 2.4 Orally Administered Vaccine Industry Restraints
3 Orally Administered Vaccine Market by Manufacturers
  1. 3.1 Global Orally Administered Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Orally Administered Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Orally Administered Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Orally Administered Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Orally Administered Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Orally Administered Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Orally Administered Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Orally Administered Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Orally Administered Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Orally Administered Vaccine Tier 1, Tier 2, and Tier 3
4 Orally Administered Vaccine Market by Type
  1. 4.1 Orally Administered Vaccine Type Introduction
  2. 4.1.1 Rotavirus Vaccine
  3. 4.1.2 Oral Polio Vaccine
  4. 4.1.3 Cholera Vaccine
  5. 4.1.4 Other
  6. 4.2 Global Orally Administered Vaccine Sales by Type
  7. 4.2.1 Global Orally Administered Vaccine Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Orally Administered Vaccine Sales by Type (2021-2032)
  9. 4.2.3 Global Orally Administered Vaccine Sales Market Share by Type (2021-2032)
  10. 4.3 Global Orally Administered Vaccine Revenue by Type
  11. 4.3.1 Global Orally Administered Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Orally Administered Vaccine Revenue by Type (2021-2032)
  13. 4.3.3 Global Orally Administered Vaccine Revenue Market Share by Type (2021-2032)
5 Orally Administered Vaccine Market by Application
  1. 5.1 Orally Administered Vaccine Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Orally Administered Vaccine Sales by Application
  5. 5.2.1 Global Orally Administered Vaccine Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Orally Administered Vaccine Sales by Application (2021-2032)
  7. 5.2.3 Global Orally Administered Vaccine Sales Market Share by Application (2021-2032)
  8. 5.3 Global Orally Administered Vaccine Revenue by Application
  9. 5.3.1 Global Orally Administered Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Orally Administered Vaccine Revenue by Application (2021-2032)
  11. 5.3.3 Global Orally Administered Vaccine Revenue Market Share by Application (2021-2032)
6 Global Orally Administered Vaccine Sales by Region
  1. 6.1 Global Orally Administered Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orally Administered Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Orally Administered Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Orally Administered Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Orally Administered Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Orally Administered Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Orally Administered Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Orally Administered Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Orally Administered Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Orally Administered Vaccine Revenue by Region
  1. 7.1 Global Orally Administered Vaccine Revenue by Region
  2. 7.1.1 Global Orally Administered Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Orally Administered Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Orally Administered Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Orally Administered Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Orally Administered Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Orally Administered Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Orally Administered Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Orally Administered Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Orally Administered Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Lanzhou Institute
  2. 8.1.1 Lanzhou Institute Company Information
  3. 8.1.2 Lanzhou Institute Business Overview
  4. 8.1.3 Lanzhou Institute Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Lanzhou Institute Orally Administered Vaccine Product Portfolio
  6. 8.1.5 Lanzhou Institute Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Orally Administered Vaccine Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Orally Administered Vaccine Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GSK Orally Administered Vaccine Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Tiantan Biological
  26. 8.5.1 Tiantan Biological Company Information
  27. 8.5.2 Tiantan Biological Business Overview
  28. 8.5.3 Tiantan Biological Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tiantan Biological Orally Administered Vaccine Product Portfolio
  30. 8.5.5 Tiantan Biological Recent Developments
  31. 8.6 Valneva
  32. 8.6.1 Valneva Company Information
  33. 8.6.2 Valneva Business Overview
  34. 8.6.3 Valneva Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Valneva Orally Administered Vaccine Product Portfolio
  36. 8.6.5 Valneva Recent Developments
  37. 8.7 Vabiotech
  38. 8.7.1 Vabiotech Company Information
  39. 8.7.2 Vabiotech Business Overview
  40. 8.7.3 Vabiotech Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vabiotech Orally Administered Vaccine Product Portfolio
  42. 8.7.5 Vabiotech Recent Developments
  43. 8.8 Shanghai United Cell
  44. 8.8.1 Shanghai United Cell Company Information
  45. 8.8.2 Shanghai United Cell Business Overview
  46. 8.8.3 Shanghai United Cell Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanghai United Cell Orally Administered Vaccine Product Portfolio
  48. 8.8.5 Shanghai United Cell Recent Developments
  49. 8.9 Serum Institute
  50. 8.9.1 Serum Institute Company Information
  51. 8.9.2 Serum Institute Business Overview
  52. 8.9.3 Serum Institute Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Serum Institute Orally Administered Vaccine Product Portfolio
  54. 8.9.5 Serum Institute Recent Developments
  55. 8.10 PaxVax
  56. 8.10.1 PaxVax Company Information
  57. 8.10.2 PaxVax Business Overview
  58. 8.10.3 PaxVax Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 PaxVax Orally Administered Vaccine Product Portfolio
  60. 8.10.5 PaxVax Recent Developments
  61. 8.11 Panacea Biotec Ltd
  62. 8.11.1 Panacea Biotec Ltd Company Information
  63. 8.11.2 Panacea Biotec Ltd Business Overview
  64. 8.11.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio
  66. 8.11.5 Panacea Biotec Ltd Recent Developments
  67. 8.12 Halfkin Bio-Pharmaceuticals
  68. 8.12.1 Halfkin Bio-Pharmaceuticals Company Information
  69. 8.12.2 Halfkin Bio-Pharmaceuticals Business Overview
  70. 8.12.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio
  72. 8.12.5 Halfkin Bio-Pharmaceuticals Recent Developments
  73. 8.13 EuBiologics
  74. 8.13.1 EuBiologics Company Information
  75. 8.13.2 EuBiologics Business Overview
  76. 8.13.3 EuBiologics Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 EuBiologics Orally Administered Vaccine Product Portfolio
  78. 8.13.5 EuBiologics Recent Developments
  79. 8.14 Bio-Med
  80. 8.14.1 Bio-Med Company Information
  81. 8.14.2 Bio-Med Business Overview
  82. 8.14.3 Bio-Med Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bio-Med Orally Administered Vaccine Product Portfolio
  84. 8.14.5 Bio-Med Recent Developments
  85. 8.15 Bibcol
  86. 8.15.1 Bibcol Company Information
  87. 8.15.2 Bibcol Business Overview
  88. 8.15.3 Bibcol Orally Administered Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bibcol Orally Administered Vaccine Product Portfolio
  90. 8.15.5 Bibcol Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Orally Administered Vaccine Value Chain Analysis
  2. 9.1.1 Orally Administered Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Orally Administered Vaccine Production Mode & Process
  6. 9.2 Orally Administered Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Orally Administered Vaccine Distributors
  9. 9.2.3 Orally Administered Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst